Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

References

• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol. 2007;5:873–882.
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet. 2005;366:1561–1577.
   PubMed Web of Science ®Google Scholar
• le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:1953–1957.
   PubMed Web of Science ®Google Scholar
• Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017;31:e12867.
   Web of Science ®Google Scholar
• Fernandez-Guerrero ML, Robles P, Rivas P, et al. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop. 2004;90:11–16.
   PubMed Web of Science ®Google Scholar
• Pasquau F, Ena J, Sanchez R, et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis. 2005;24:411–418.
   PubMed Web of Science ®Google Scholar
• Basset D, Faraut F, Marty P, et al. Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature. Microbes Infect. 2005;7:1370–1375.
   PubMed Web of Science ®Google Scholar
• Agteresch HJ, van ’t Veer MB, Cornelissen JJ, et al. Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:391–393.
   PubMed Web of Science ®Google Scholar
• Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E, et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant. 2004;33:667–668.
   PubMed Web of Science ®Google Scholar
• Bautista G, Ramos A, Gil S. Visceral leishmaniasis in hematopoietic stem cell transplantation. Transpl Int. 2012;25:e83–e85.
   PubMed Web of Science ®Google Scholar
• Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191–199.
   PubMed Web of Science ®Google Scholar
• Pitini V, Cascio A, Arrigo C, et al. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol. 2012;156:1.
   PubMed Web of Science ®Google Scholar
• Casabianca A, Marchetti M, Zallio F, et al. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection. 2011;39:375–378.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kastritis E, et al. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia. 2014;28:928–934.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Carrillo E, Lopez-Velez R, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014;20:286–299.
   PubMed Web of Science ®Google Scholar
• Erre GL, Mesina P, Tonelli N, et al. Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol. 2010;28:590–591.
   PubMed Web of Science ®Google Scholar
• Pittalis S, Nicastri E, Spinazzola F, et al. Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis. 2006;6:177.
   PubMed Web of Science ®Google Scholar
• Pintado V, Martin-Rabadan P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore). 2001;80:54–73.
   PubMed Web of Science ®Google Scholar
• Ribera E, Ocana I, de Otero J, et al. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med. 1996;100:496–501.
   PubMed Web of Science ®Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9:604–615.
   PubMed Web of Science ®Google Scholar
• Gupta G, Oghumu S, Satoskar AR. Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol. 2013;82:155–184.
   PubMed Web of Science ®Google Scholar
• Meier CA. Mechanisms of immunosuppression by glucocorticoids. Eur J Endocrinol. 1996;134:50.
   PubMed Web of Science ®Google Scholar
• Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–290.
   PubMed Web of Science ®Google Scholar
• Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?. Oncoimmunology. 2012;1:372–374.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Krieg S, Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol. 2012;3:388.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma. 2012;53:1406–1408.
   PubMed Web of Science ®Google Scholar
• Piro E, Kropp M, Cantaffa R, et al. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib. Ann Hematol. 2012;91:1827–1828.
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Hundemer M, Eisenbach C, et al. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant. Leuk Lymphoma. 2014;55:2967–2969.
   PubMed Web of Science ®Google Scholar
• Alahmadi M, Chin-Yee IH, Gupta K, et al. Leishmaniasis involving the bone marrow of a patient with multiple myeloma. Ann Hematol. 2015;94:1417–1418.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–394.
   PubMed Web of Science ®Google Scholar
• Weisel K. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. Onco Targets Ther. 2016;9:6037–6048.
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88:168–177.
   PubMed Web of Science ®Google Scholar
• Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol. 2010;125:S324–S335.
   PubMed Web of Science ®Google Scholar
• Dosani T, Carlsten M, Maric I, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J. 2015;5:e306.
   PubMed Web of Science ®Google Scholar